Pharmacotherapy - methadone, buprenorphine, or naltrexone - is an evidence-based treatment for opioid use disorder, but little is known about receipt of these medications among veterans involved in the justice system. The current study examines receipt of pharmacotherapy for opioid use disorder among veterans with a history of justice involvement at U.S. Veterans Health Administration (VHA) facilities compared to veterans with no justice involvement.Using national VHA clinical and pharmacy records, we conducted a retrospective cohort study of veterans with an opioid use disorder diagnosis in fiscal year 2012. Using a mixed-effects logistic regression model, we examined receipt of pharmacotherapy in the 1-year period following diagnosis as a function of justice involvement, adjusting for patient and facility characteristics.The 1-year rate of receipt for pharmacotherapy for opioid use disorder was 27

作者：Andrea K, Finlay；Alex H S, Harris；Joel, Rosenthal；Jessica, Blue-Howells；Sean, Clark；Jim, McGuire；Christine, Timko；Susan M, Frayne；David, Smelson；Elizabeth, Oliva；Ingrid, Binswanger

来源：Drug and alcohol dependence 2016 年 160卷